Embed Size (px)
DESCRIPTION
The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%. Browse this report: http://mrr.cm/Zim
Citation preview
www.MarketResearchReports.com
Insulin Delivery Devices Market to 2019 - Simplified
Pump Solutions and Low Cost Pens
Represent Distinct Regional Growth
Drivers
Category : Medical Devices
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Introduction to Report
Launch Date: April 4, 2014
Number of Pages: 121
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 3,500
Price For Site User License: USD 7,000
Price For Global User License: USD 10,500
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com
About the Report
Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers report looks at the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories.
It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics.
www.MarketResearchReports.com
Research Findings
The global insulin delivery devices market was valued at $8.8 billion in 2012 and is forecast to reach $13.8 billion by 2019, at a CAGR of 7%.
Emerging economies such as India and China are expected to grow at the fastest pace during the 2012-2019 forecast period.
The use of pre-filled cartridges eliminates the need for insulin reservoirs and reduces the weight of the insulin pump by 25%.
Currently, the top two players, Medtronic and Animas Corporation, account for 80% of insulin pump sales in the US. Insulet Corporation, with its flagship insulin pump OmniPod, holds about 15% of the market, while other small players such as Tandem, Asante and Roche hold a combined market share of 5%.
The Research estimates, competitive conversions will account for about 60% of the sales generated by new entrants such as Insulet Corporation, Tandem Diagnostics and Asante in the future. Patients who are new to insulin pump therapy will contribute close to 40% of the sales generated by new entrants.
www.MarketResearchReports.com
Research Findings Continues…
The worldwide prevalence of diabetes in 2013 was 381.8 million, and this is projected to increase by 55% to 591.1 million by 2035. It is also estimated that 175 million diabetics remain undiagnosed, which accounts for 46% of all diabetics worldwide.
China had a diabetes prevalence of 98.4 million, followed by India with 65.1 million and the US with 24.4 million.
At the current rate, diabetes prevalence in China is expected to increase to 142.7 million by 2035, while in India it is expected to rise to 109 million by 2035. In 2013, the US spent $239 billion on diabetes, accounting for 36% of its healthcare expenditure, while China, the country with the highest number of diabetics globally, spent only $38 billion on diabetes, accounting for 7% of its healthcare costs.
www.MarketResearchReports.com
Research Findings Continues…
The study showed that the annual cost of providing insulin pumps was projected from $8.6 billion in 2012 to $15.1 billion by 2032. The annual cost of treatment for serious complications from diabetes was projected from $8.8 billion in 2012 to $25.1 billion by 2032.
These are the direct costs related to the management of serious complications from diabetes. Considering only the direct costs, government investment in insulin pumps could save $200,000 in 2012 and $10 billion by 2032.
Taking indirect costs into account, such as costs associated with mortality and disability arising from diabetes, the net savings will increase to $800,000 in 2012 and $10.8 billion by 2032.
www.MarketResearchReports.com
Report Coverage Table of Contents Introduction Diabetes – Disease Overview Diabetes – Epidemiology Global Insulin Delivery Devices Market: Device Overview Global Insulin Delivery Devices Market: Market
Characterization Global Insulin Delivery Devices Market: Segment Analysis and
Forecasts Global Insulin Delivery Devices Market: Country Analysis and
Forecasts Global Insulin Delivery Devices Market: Reimbursement
System Global Insulin Delivery Devices Market: Competitive
Landscape Global Insulin Delivery Devices Market: Product Pipeline
Analysis Global Insulin Delivery Devices Market: Consolidation
Landscape Appendix
www.MarketResearchReports.com
Company Coverage
1. Novo Nordisk (Subsidiary of Novo A/S)2. Sanofi3. Eli Lilly4. Medtronic5. Becton, Dickinson and Company6. Animas7. F. Hoffmann-La Roche8. Insulet9. Asante Solutions10. Abbott Laboratories11. Ypsomed12. Owen Mumford13. Bioject Medical Technologies14. Injex - Equidyne Systems15. Antares Pharma16. Tandem Diabetes Care17. Tonghua Dongbao Pharmaceutical18. Shanghai Fosun Pharmaceutical
www.MarketResearchReports.com
Custom Research: Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.
For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and purchase this publication:
http://mrr.cm/Zim
About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.
Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)
